These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 12220962)

  • 21. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan.
    Locatelli F; Palmer BF; Kashihara N; Ecder T
    Curr Med Res Opin; 2009 Dec; 25(12):2933-49. PubMed ID: 19835466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
    Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN;
    J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hypertension, obesity, erectile dysfunction. What kind of drug to choose].
    Maksimov ML; Ermolaeva AS; Dralova OV
    Kardiologiia; 2011; 51(7):58-64. PubMed ID: 21878087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VALIANT and EUROPA.
    Liebson PR
    Prev Cardiol; 2004; 7(1):42-4. PubMed ID: 15010627
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
    Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
    Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
    Hershon KS
    Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
    Ramahi TM
    Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic potential of angiotensin receptor blockers in hypertension.
    Cheung BM
    Expert Opin Investig Drugs; 2006 Jun; 15(6):625-35. PubMed ID: 16732715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual renin angiotensin system blockade in patients with acute myocardial infarction and preserved left ventricular systolic function.
    Suşan M; Petrescu L; Riviş AI; Suşan RM; Burghină D; Dan R; Cozma D; Drăgulescu SI
    Rom J Intern Med; 2005; 43(3-4):187-98. PubMed ID: 16812979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valsartan: a novel angiotensin type 1 receptor antagonist.
    Thürmann PA
    Expert Opin Pharmacother; 2000 Jan; 1(2):337-50. PubMed ID: 11249553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects.
    Silverstein RL; Fenves AZ; Ram CV
    Postgrad Med; 2004 Aug; 116(2):31-8, 41. PubMed ID: 15323152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials.
    Mistry NB; Westheim AS; Kjeldsen SE
    Expert Opin Pharmacother; 2006 Apr; 7(5):575-81. PubMed ID: 16553573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease.
    Mochizuki S; Shimizu M; Taniguchi I; Kanae K; Yoshida S; Tajima N; Dahlöf B;
    Cardiovasc Drugs Ther; 2004 Jul; 18(4):305-9. PubMed ID: 15367828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin II receptor antagonists in chronic heart failure: where do they fit?
    Houghton AR
    Drugs; 2002; 62(10):1433-40. PubMed ID: 12093312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.